Summary
Beta-blockers have become more widely used in dermatology since the publication in 2008 of the spectacular results obtained with propranolol in the treatment of infantile haemangioma by a Bordeaux team in 2008. This chance discovery in a child with corticosteroid-induced hypertrophic myocardiopathy has since been confirmed in several publications worldwide and has completely changed the management of infantile haemangioma.
It also adds to the list of indications of propranolol, a list which has grown consistently since the beta-blocker was discovered by Sir James Black II in 1965 (for which he was awarded the Nobel Prize for Physiology and Medicine in 1988).
×
N.B. : This limited content is for the general public. If you are a health professional, click here to register for free and gain access to a dedicated deeper content.
If you already have an account, log in!
Therapeutics in Dermatology, Fondation René Touraine © 2001-2012
